Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is launching the new VisioNize® box 2,
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
Alembic Pharmaceutica
Since it’s an ingredient in so many foods, you h
In a world constantly in motion, Microbioz India r
The Eastern Economic Forum, which took place from September 3 to September 6, 2025, in Vladivostok and is known for its landmark announcements, heard for the first time about Russia’s mRNA-based cancer vaccine, Enteromix, from the Federal Medical and Biological Agency (FMBA) of Russia. As per the available information, the vaccine has passed the preclinical trials and has demonstrated high efficacy and safety
As per the head of the FMBA Veronika Skvortsova, the studies on the vaccine were conducted for several years. Out of which, the last three years were focused on rigorously testing the vaccine in preclinical studies. These studies demonstrated that the vaccine caused a decrease in the size and the rate of progression of the tumor in the range of 60 to 80% depending on the disease and the increase of the survival rate.
Enteromix is Russia’s first colon cancer vaccine and it is built in mRNA technology. Enteromix is designed to be a next-generation immunotherapeutic therapy of colon cancer that aims to selectively destroy cancer cells and preserve normal tissues.
Going forward, Enteromix has completed all the preclinical stages, although it still has to gain the Health Ministry’s final approval before entering the public marketplace for medical substrate purchase. The FMBA maintained the only criteria left is the approval.
Fortunately, the focus of the research is not limited to colorectal cancer. Other Russian researchers have also made strides towards the development of vaccines for other aggressive tumors, including glioblastoma and certain forms of melanoma, particularly ocular melanoma, which are both in the advanced stages of development.
Currently, colon cancer is the third most prevalent cancer in the world, constituting 10% of all cancer cases, and the second most deadly. It has risen in incidence rate among the young population and therefore it is a serious issue in public health. Enteromix is the first and only vaccine available, and it is highly specialized, targeted, and effective. This vaccine has the possibility to reform treatment paradigms and medical outcomes for the population.
If the vaccine is approved in a timely manner, Enteromix has the possibility to become the first personalized, publically available, mRNA cancer vaccine, a differentiation step in the world of oncology. In addition, all the international experts waiting for the more robust data, which includes the result of clinical trials on humans, might also have their expectations in the general approach to treating cancer.
